Enterprise Value
2.367B
Cash
356.2M
Avg Qtr Burn
-96.07M
Short % of Float
28.42%
Insider Ownership
0.54%
Institutional Own.
89.38%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMTAGVI™ (Lifileucel) Details Melanoma, Cancer | Approved Quarterly sales | |
Iovance TIL (LN-145) Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
Iovance TIL (LN-145) or lifileucel +/- pembrolizumab Details Cancer, Non-small cell lung carcinoma, Melanoma | Phase 2 Update | |
Lifileucel Details Cancer, Cervical cancer | Phase 2 Update | |
Iovance TIL (LN-145) Details Cancer, Endometrial cancer | Phase 2 Initiation | |
IOV-4001 Details Non-small cell lung carcinoma, Cancer, Melanoma | Phase 1/2 Update |